NCT05505955View on ClinicalTrials.gov

Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency

PHASE1CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

October 8, 2022

Primary Completion Date

November 3, 2023

Study Completion Date

November 3, 2023

Conditions
Glomerulonephritis
Interventions
DRUG

HRS-5965

Subjects took HRS5965 tablets in Part 1, Part 2 and Part 3.

DRUG

Placebo

Subjects took Placebo in Part 1 and Part 2.

Trial Locations (1)

266000

The Affiliated hospital of QingDao University, Qingdao

All Listed Sponsors
lead

Chengdu Suncadia Medicine Co., Ltd.

INDUSTRY